Lori J. Wirth
Experienced in Ewing Sarcoma

Dr. Lori J. Wirth

Oncology | Hematology Oncology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
 (2562.0 mi)
Accepting New Patients
Offers Telehealth
Experienced in Ewing Sarcoma
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
 (2562.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Lori Wirth is an Oncologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Wirth and is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Thyroid Cancer, Medullary Thyroid Carcinoma, Papillary Thyroid Cancer, Thyroidectomy, and Tissue Biopsy. Dr. Wirth is currently accepting new patients.

Her clinical research consists of co-authoring 147 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Massachusetts Eye And Ear Infirmary -
North Shore Medical Center -
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Tufts
  •  Cigna
  •  Aetna
  •  Blue Cross Blue Shield
  •  Anthem
  •  UnitedHealthcare
View 1 More Insurance +

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114
Other Locations
MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
243 Charles St, Suite 1107, Boston, MA 02114
THE GENERAL HOSPITAL CORPORATION
104 Endicott St, Danvers, MA 01923

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Selumetinib, Iodine-131
Study Phase: Phase 2
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Enrollment Status: Active_not_recruiting
Publish Date: May 30, 2024
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drugs: Decitabine, Durvalumab
Study Phase: Phase 1/Phase 2
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Biological
Study Drugs: Autologous Epstein Barr Virus-Specific Cytotoxic T Cells, Gemcitabine, Carboplatin
Study Phase: Phase 3
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Enrollment Status: Completed
Publish Date: October 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
Enrollment Status: Completed
Publish Date: May 25, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 10 Less Clinical Trials

147 Total Publications

Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy.
Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy.
Journal: JCO precision oncology
Published: January 27, 2025
Similar Doctors
Elite in Ewing Sarcoma
Dr. Edwin Choy
Hematology Oncology | Oncology
Elite in Ewing Sarcoma
Dr. Edwin Choy
Hematology Oncology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Choy and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Osteosarcoma, and Chordoma. Dr. Choy is currently accepting new patients.

Elite in Ewing Sarcoma
Dr. Katherine A. Janeway
Pediatric Hematology Oncology | Pediatrics | Hematology
Elite in Ewing Sarcoma
Dr. Katherine A. Janeway
Pediatric Hematology Oncology | Pediatrics | Hematology
Dana Farber Cancer Institute, 44 Binney Street, 
Boston, MA 
 (2.6 mi)
617-632-4994
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Katherine Janeway is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Boston, Massachusetts. Dr. Janeway and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroepithelioma, and Bone Marrow Aspiration. Dr. Janeway is currently accepting new patients.

Distinguished in Ewing Sarcoma
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology
Distinguished in Ewing Sarcoma
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
617-724-0287
Languages Spoken:
English
Offers Telehealth

Gregory Cote is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Cote and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Chordoma, Epithelioid Sarcoma, Synovial Sarcoma, and Tissue Biopsy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile